Valsartan is an angiotensin II receptor blocker (ARB) commonly prescribed for treating hypertension and heart failure. It works by selectively blocking the binding of angiotensin II to its receptors, thereby inhibiting its vasoconstrictive and aldosterone-secreting effects. This reduces blood pressure by relaxing and dilating blood vessels, leading to decreased resistance to blood flow and reduced blood pressure levels. Valsartan is also prescribed for congestive heart failure, which impairs the heart's ability to efficiently pump blood due to various underlying causes.

Valsartan's efficacy and safety have been extensively studied in clinical trials, demonstrating its effectiveness in lowering blood pressure and improving heart failure symptoms. It is often used as a first-line treatment for hypertension and is commonly prescribed in heart failure patients who cannot tolerate angiotensin-converting enzyme (ACE) inhibitors or require additional therapy alongside ACE inhibitors. Although Valsartan is primarily indicated for hypertension and heart failure, it may also be used off-label for other medical conditions, such as reducing proteinuria in patients with diabetic nephropathy or chronic kidney disease. Common side effects include dizziness, fatigue, cough, and gastrointestinal disturbances. Serious adverse events are rare but may include allergic reactions, kidney problems, or liver dysfunction. Valsartan, an angiotensin II receptor blocker, has been shown to have anti-inflammatory benefits in animal models of inflammation. It has been proven to reduce the levels of pro-inflammatory cytokines such as TNF-α and IL-6, as well as block leukocyte infiltration and activation. Clinical observations have also indicated potential anti-inflammatory effects of Valsartan, with reductions in inflammatory markers in certain patient populations, such as those with hypertension or heart failure. This study aims to assess the pharmacological effects of Valsartan as an anti-hypertensive agent and explore its potential role as an anti-inflammatory agent in patients with stable hemodynamic circumstances.

A prospective pharmacological interventional pilot study was conducted in a monocentric, non-profit setting. After obtaining informed written consent for the anonymous collection and transmission of data, we included consecutive patients with stable hemodynamic conditions who were qualified for S/V treatment in accordance with the Guidelines. All patients at the Al-Hussien Teaching Hospital in Karbala, Iraq, were observed between 2022 and 2023. 

Prior to S/V, all patients were undergoing optimal medical therapy (OMT), which included beta receptor blockers, ACEI inhibitors, or ARBs, and MRAs. Systolic blood pressure (SBP) of at least 100 mm Hg, no need for an increase in intravenous diuretic dose, no need for intravenous vasodilator injections in the preceding 6 hours, and no need for intravenous inotropes in the prior 24 hours were all indicators of hemodynamic stability. Patients who were pregnant, under the age of 18, had complicated congenital heart disease, cardiac transplants, or were implanted with ventricular assist devices were also excluded. All study protocols were approved by the Partners Healthcare Institutional Review Board and were carried out in accordance with the Helsinki Declaration..

Statistical Analysis 

The Microsoft Excel package contains all of the data on the patients who were observed. All of the study's hypotheses were confirmed using the statistical tools SPSS and Statistics. The statistical tests performed for the evaluation were judged significant () at a two-tailed probability level of significance of 95% (p 0.05). The tests (parametric and non-parametric) were chosen after the Kolmogorov-Smirnov test confirmed that the data were regularly distributed. To confirm the variables observed across the time range T0-T30-T60, the method of analysis of variance for repeated measurements (Anova approach) was utilized. The Tukey multiple comparison approach was used to establish whether or not there was a statistically significant difference between the times. While the T tests are used to determine the variables

Demographic Data 

The mean of age group was ± 46.89. The result showed that the age group were near equal between two groups (25-65). The result showed that the gender was near equal. The mean of the BMI was ± 33.24and the most of patients were obese body built (44.8%) as showed in the table below: 

As shown in the table below, the frequencies of valsartan and the mean of interleukin 6 (IL6) of the patients were 0.95187.

The relationship between IL6 and other factors was determined using pearson-corlation and the p value, as shown in the table below.

The association between the interleukin 6 and the valsartan and by chi square test was significant and the p value was 0.011. 

Table 1: Demographic Data 

Figure 1: Percentage of Age Group

Table 2: The Frequencies of Valsartan

The association between the il6 and other variables

Figure 2: Percentage of Gender 

Table 3: The Association between Variables

The association between the valsartan and other variables

Figure 3: Percentage of BMI

Table 4: The Association between the Valsartan and other Variables

The results of the study provide valuable insights into the demographic characteristics of the participants and the associations between variables. In terms of demographic data, the mean age of the participants was approximately 46.89, with a relatively equal distribution between the age groups of 25-45 and 46-65. Similarly, the gender distribution was also nearly equal, with 64.4% male and 35.6% female participants. The mean BMI was approximately 33.24, indicating that the majority of patients (44.8%) were classified as obese.

Additionally, the study examined the frequencies of valsartan usage among the participants. Out of the total 87 participants, 63.2% received valsartan, while 36.8% did not.

The association between interleukin 6 (IL6) and other variables was assessed using Pearson correlation analysis. The results showed no significant correlations between IL6 and age or BMI. Regarding the association between valsartan and IL6, the chi-square test indicated a significant relationship with a p-value of 0.011. This suggests that there is an association between the use of valsartan and IL6 levels. However, no significant associations were found between valsartan and gender or age group. When comparing these findings with other studies, it is crucial to consider the specific research question, methodology, and population characteristics of each study. This allows for a comprehensive evaluation of the consistency or divergence of results across different studies.

The result indicating a significant association between BMI and valsartan (p = 0.001). There are several possible explanations for this significant association. First, it is plausible that the use of valsartan may lead to changes in body weight or composition, potentially resulting in alterations in BMI. Valsartan's mechanism of action in blocking angiotensin II receptors may have an influence on fluid balance, sodium excretion, or metabolic processes, which can indirectly affect BMI. Secondly, it is also possible that individuals with higher BMIs are more likely to be prescribed valsartan due to their higher risk of hypertension or cardiovascular conditions. In this case, the significant association could be reflective of the underlying health conditions associated with higher BMI rather than a direct effect of valsartan on BMI.

However, it is important to note that this study's findings are specific to the study population and should not be generalized without further research. Additionally, the nature of the association between BMI and valsartan requires more investigation to determine causality and to establish the clinical significance of this relationship.[10]

In summary, the study revealed important demographic data and associations between variables in the study population. The participants had a relatively equal distribution of age and gender. The majority of patients were classified as obese based on their BMI. The use of valsartan was associated with IL6 levels. However, to draw more robust conclusions, further research and comparisons with other studies are needed.

The association between interleukin 6 (IL6) and other variables, such as age and BMI, did not show significant correlations in this study. This suggests that IL6 levels may not be strongly influenced by age or BMI in the study population. However, it is important to consider that these results may vary in different populations or with larger sample sizes.

Furthermore, the study revealed a significant association between the use of valsartan and IL6 levels. This finding implies that valsartan may affect IL6 levels in the research population. More research, however, is required to understand the underlying mechanisms and to corroborate these findings in larger and more diverse groups.

1. Parving, H.H. and F. Persson. “Aliskiren combined with losartan in type 2 diabetes and nephropathy.” N Engl J Med, vol. 358, no. 23, 2008, pp. 2433–2446.

2. Nussberger, J. et al. “Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.” Hypertension, vol. 51, no. 5, 2008, pp. 1306–1311.

3. McMurray, J.J. et al. “Aliskiren, enalapril, or aliskiren and enalapril in heart failure.” N Engl J Med, vol. 374, no. 16, 2016, pp. 1521–1532.

4. Zhou, M.S. et al. “Vascular and renal mechanisms of hypertension: role of angiotensin II.” J Am Soc Nephrol, vol. 17, no. 12 Suppl 3, 2006, pp. S258–263.

5. Schieffer, B. et al. “Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction.” Circ Res, vol. 87, no. 12, 2000, pp. 1195–1201.

6. Luo, P. et al. “Valsartan regulates the innate immune response via nuclear factor-kappa B signaling pathway in rats with myocardial infarction.” Am J Transl Res, vol. 9, no. 4, 2017, pp. 1647–1658.

7. Wu, L. et al. “Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury.” Circulation, vol. 104, no. 21, 2001, pp. 2716–2721.

8. Dharmashankar, K. and M.E. Widlansky. “Vascular endothelial function and hypertension: insights and directions.” Curr Hypertens Rep, vol. 12, no. 6, 2010, pp. 448–455.

9. Li, Y. et al. “Antioxidants significantly improve the clinical manifestations of a rat model of multiple sclerosis.” Mol Neurobiol, vol. 53, no. 6, 2016, pp. 3831–3839.

10. Ge, B. et al. “Effectiveness of valsartan/amlodipine single-pill combination in hypertensive patients with excess body weight: Subanalysis of China STATUS II.” J Cardiovasc Pharmacol, vol. 66, no. 5, 2015, pp. 497–503. doi:10.1097/FJC.0000000000000301.

Valsartan is an angiotensin II receptor blocker (ARB) commonly prescribed for treating hypertension and heart failure. It works by selectively blocking the binding of angiotensin II to its receptors, thereby inhibiting its vasoconstrictive and aldosterone-secreting effects. This reduces blood pressure by relaxing and dilating blood vessels, leading to decreased resistance to blood flow and reduced blood pressure levels. Valsartan is also prescribed for congestive heart failure, which impairs the heart's ability to efficiently pump blood due to various underlying causes.

Valsartan's efficacy and safety have been extensively studied in clinical trials, demonstrating its effectiveness in lowering blood pressure and improving heart failure symptoms. It is often used as a first-line treatment for hypertension and is commonly prescribed in heart failure patients who cannot tolerate angiotensin-converting enzyme (ACE) inhibitors or require additional therapy alongside ACE inhibitors. Although Valsartan is primarily indicated for hypertension and heart failure, it may also be used off-label for other medical conditions, such as reducing proteinuria in patients with diabetic nephropathy or chronic kidney disease. Common side effects include dizziness, fatigue, cough, and gastrointestinal disturbances. Serious adverse events are rare but may include allergic reactions, kidney problems, or liver dysfunction. Valsartan, an angiotensin II receptor blocker, has been shown to have anti-inflammatory benefits in animal models of inflammation. It has been proven to reduce the levels of pro-inflammatory cytokines such as TNF-α and IL-6, as well as block leukocyte infiltration and activation. Clinical observations have also indicated potential anti-inflammatory effects of Valsartan, with reductions in inflammatory markers in certain patient populations, such as those with hypertension or heart failure. This study aims to assess the pharmacological effects of Valsartan as an anti-hypertensive agent and explore its potential role as an anti-inflammatory agent in patients with stable hemodynamic circumstances.

A prospective pharmacological interventional pilot study was conducted in a monocentric, non-profit setting. After obtaining informed written consent for the anonymous collection and transmission of data, we included consecutive patients with stable hemodynamic conditions who were qualified for S/V treatment in accordance with the Guidelines. All patients at the Al-Hussien Teaching Hospital in Karbala, Iraq, were observed between 2022 and 2023. 

Prior to S/V, all patients were undergoing optimal medical therapy (OMT), which included beta receptor blockers, ACEI inhibitors, or ARBs, and MRAs. Systolic blood pressure (SBP) of at least 100 mm Hg, no need for an increase in intravenous diuretic dose, no need for intravenous vasodilator injections in the preceding 6 hours, and no need for intravenous inotropes in the prior 24 hours were all indicators of hemodynamic stability. Patients who were pregnant, under the age of 18, had complicated congenital heart disease, cardiac transplants, or were implanted with ventricular assist devices were also excluded. All study protocols were approved by the Partners Healthcare Institutional Review Board and were carried out in accordance with the Helsinki Declaration..

Statistical Analysis 

The Microsoft Excel package contains all of the data on the patients who were observed. All of the study's hypotheses were confirmed using the statistical tools SPSS and Statistics. The statistical tests performed for the evaluation were judged significant () at a two-tailed probability level of significance of 95% (p 0.05). The tests (parametric and non-parametric) were chosen after the Kolmogorov-Smirnov test confirmed that the data were regularly distributed. To confirm the variables observed across the time range T0-T30-T60, the method of analysis of variance for repeated measurements (Anova approach) was utilized. The Tukey multiple comparison approach was used to establish whether or not there was a statistically significant difference between the times. While the T tests are used to determine the variables.

Demographic Data 

The mean of age group was ± 46.89. The result showed that the age group were near equal between two groups (25-65). The result showed that the gender was near equal. The mean of the BMI was ± 33.24and the most of patients were obese body built (44.8%) as showed in the table below: 

Table 1: Demographic Data 

Figure 1: Percentage of Age Group

As shown in the table below, the frequencies of valsartan and the mean of interleukin 6 (IL6) of the patients were 0.95187.

Table 2: The Frequencies of Valsartan

Figure 2: Percentage of Gender

The association between the il6 and other variables

The relationship between IL6 and other factors was determined using pearson-corlation and the p value, as shown in the table below.

Table 3: The Association between Variables

The association between the valsartan and other variables

The association between the interleukin 6 and the valsartan and by chi square test was significant and the p value was 0.011. 

Table 4: The Association between the Valsartan and other Variables

Figure 3: Percentage of BMI 

The results of the study provide valuable insights into the demographic characteristics of the participants and the associations between variables. In terms of demographic data, the mean age of the participants was approximately 46.89, with a relatively equal distribution between the age groups of 25-45 and 46-65. Similarly, the gender distribution was also nearly equal, with 64.4% male and 35.6% female participants. The mean BMI was approximately 33.24, indicating that the majority of patients (44.8%) were classified as obese.

Additionally, the study examined the frequencies of valsartan usage among the participants. Out of the total 87 participants, 63.2% received valsartan, while 36.8% did not.

The association between interleukin 6 (IL6) and other variables was assessed using Pearson correlation analysis. The results showed no significant correlations between IL6 and age or BMI. Regarding the association between valsartan and IL6, the chi-square test indicated a significant relationship with a p-value of 0.011. This suggests that there is an association between the use of valsartan and IL6 levels. However, no significant associations were found between valsartan and gender or age group. When comparing these findings with other studies, it is crucial to consider the specific research question, methodology, and population characteristics of each study. This allows for a comprehensive evaluation of the consistency or divergence of results across different studies.

The result indicating a significant association between BMI and valsartan (p = 0.001). There are several possible explanations for this significant association. First, it is plausible that the use of valsartan may lead to changes in body weight or composition, potentially resulting in alterations in BMI. Valsartan's mechanism of action in blocking angiotensin II receptors may have an influence on fluid balance, sodium excretion, or metabolic processes, which can indirectly affect BMI. Secondly, it is also possible that individuals with higher BMIs are more likely to be prescribed valsartan due to their higher risk of hypertension or cardiovascular conditions. In this case, the significant association could be reflective of the underlying health conditions associated with higher BMI rather than a direct effect of valsartan on BMI.

However, it is important to note that this study's findings are specific to the study population and should not be generalized without further research. Additionally, the nature of the association between BMI and valsartan requires more investigation to determine causality and to establish the clinical significance of this relationship.[10]

In summary, the study revealed important demographic data and associations between variables in the study population. The participants had a relatively equal distribution of age and gender. The majority of patients were classified as obese based on their BMI. The use of valsartan was associated with IL6 levels. However, to draw more robust conclusions, further research and comparisons with other studies are needed.

The association between interleukin 6 (IL6) and other variables, such as age and BMI, did not show significant correlations in this study. This suggests that IL6 levels may not be strongly influenced by age or BMI in the study population. However, it is important to consider that these results may vary in different populations or with larger sample sizes.

Furthermore, the study revealed a significant association between the use of valsartan and IL6 levels. This finding implies that valsartan may affect IL6 levels in the research population. More research, however, is required to understand the underlying mechanisms and to corroborate these findings in larger and more diverse groups.

1. Parving, H.H. and F. Persson. “Aliskiren combined with losartan in type 2 diabetes and nephropathy.” N Engl J Med, vol. 358, no. 23, 2008, pp. 2433–2446.

2. Nussberger, J. et al. “Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.” Hypertension, vol. 51, no. 5, 2008, pp. 1306–1311.

3. McMurray, J.J. et al. “Aliskiren, enalapril, or aliskiren and enalapril in heart failure.” N Engl J Med, vol. 374, no. 16, 2016, pp. 1521–1532.

4. Zhou, M.S. et al. “Vascular and renal mechanisms of hypertension: role of angiotensin II.” J Am Soc Nephrol, vol. 17, no. 12 Suppl 3, 2006, pp. S258–263.

5. Schieffer, B. et al. “Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction.” Circ Res, vol. 87, no. 12, 2000, pp. 1195–1201.

6. Luo, P. et al. “Valsartan regulates the innate immune response via nuclear factor-kappa B signaling pathway in rats with myocardial infarction.” Am J Transl Res, vol. 9, no. 4, 2017, pp. 1647–1658.

7. Wu, L. et al. “Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury.” Circulation, vol. 104, no. 21, 2001, pp. 2716–2721.

8. Dharmashankar, K. and M.E. Widlansky. “Vascular endothelial function and hypertension: insights and directions.” Curr Hypertens Rep, vol. 12, no. 6, 2010, pp. 448–455.

9. Li, Y. et al. “Antioxidants significantly improve the clinical manifestations of a rat model of multiple sclerosis.” Mol Neurobiol, vol. 53, no. 6, 2016, pp. 3831–3839.

10. Ge, B. et al. “Effectiveness of valsartan/amlodipine single-pill combination in hypertensive patients with excess body weight: Subanalysis of China STATUS II.” J Cardiovasc Pharmacol, vol. 66, no. 5, 2015, pp. 497–503. doi:10.1097/FJC.0000000000000301.